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Pentraxin 3 (PTX3) is a soluble pattern recognition receptor which is classified as a
long-pentraxin in the pentraxin family. It is known to play an important role in innate
immunity, inflammatory regulation, and female fertility. PTX3 is synthesized by specific
cells, primarily in response to inflammatory signals. Among these various cells, neutrophils
have a unique PTX3 production system. Neutrophils store PTX3 in neutrophil-specific
granules and then the stored PTX3 is released and localizes in neutrophil extracellular
traps (NETs). Although certain NET components have been identified, such as histones
and anti-microbial proteins, the detailed mechanisms by which NETs localize, as well as
capture and kill microbes, have not been fully elucidated. PTX3 is a candidate diagnostic
marker of infection and vascular damage. In severe infectious diseases such as sepsis,
the circulating PTX3 concentration increases greatly (up to 100ng/mL, i.e., up to 100-fold
of the normal level). Even though it is clearly implied that PTX3 plays a protective role in
sepsis and certain other disorders, the detailed mechanisms by which it does so remain
unclear. A proteomic study of PTX3 ligands in septic patients revealed that PTX3 forms a
complex with certain NET component proteins. This suggests a role for PTX3 in which
it facilitates the efficiency of anti-microbial protein pathogen clearance by interacting
with both pathogens and anti-microbial proteins. We discuss the possible relationships
between PTX3 and NET component proteins in the host protection afforded by the innate
immune response. The PTX3 complex has the potential to be a highly useful diagnostic
marker of sepsis and other inflammatory diseases.
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INTRODUCTION
The release of neutrophil extracellular traps (NETs), first
reported in 2004 (Brinkmann, 2004), is one of the anti-
microbial actions of neutrophils. NETs are mesh-like structures
that contain DNA as a backbone, with anti-microbial pro-
teins attached (Amulic and Hayes, 2011). NETs trap microbes
and form an anti-microbial-protein-rich microenvironment
(Medina, 2009).
Pentraxin 3 (PTX3) was reported as one of the NET com-
ponent proteins (Jaillon et al., 2007). PTX3 is a member of
pentraxin family and mainly acts as a soluble pattern recogni-
tion receptor (PRR) in the innate immune response (Bottazzi
et al., 2010). In NETs, PTX3 may participate in microbial recog-
nition by facilitating the trapping of microbes. The circulat-
ing PTX3 level is known to be increased in certain diseases,
and PTX3 may predominantly play a critical role in host pro-
tection. Interestingly, proteomic identification of the circulat-
ing PTX3 interacting proteins revealed that PTX3 formed a
complex with NET component proteins (Daigo et al., 2012).
This finding implies that the NET component proteins are
active in pathogen recognition and clearance by tethering
with each other in NETs and bloodstream. PTX3 appears
to be a key tethering molecule to enhance the actions of
NETs component proteins. In this review, we will discuss the
host-protective roles of PTX3 in relation to NETs component
proteins.
NETs
SOURCE, EXPRESSION, AND FUNCTION
Neutrophils are the major player in the innate immune system
response against microbial pathogen invasion. One of the anti-
microbial activities of neutrophils is the extrusion of NETs
(Brinkmann, 2004). NETs are formed upon the activation of
neutrophils by factors such as IL-8, lipopolysaccharide (LPS),
phorbol 12-myristate 13-acetate (PMA), bacteria, fungi, and
activated platelets (Brinkmann, 2004; Clark et al., 2007; Fuchs
et al., 2007). Neutrophil death as a result of the extrusion of
NETs is called “NETosis,” which is a cell death pathway dis-
tinct from apoptosis or necrosis (Brinkmann and Zychlinsky,
2007; Steinberg and Grinstein, 2007). The release of NETs has
also been reportedly observed without cell death (Yipp et al.,
2012). Extracellular formations of this type are also observed
in basophils and eosinophils (Schorn et al., 2012). NETs are
mesh-like structures that consist of cellular DNA, along with
bactericidal proteins, that reside in neutrophil granules and the
nucleus. These proteins are connected to DNA fibers, and form
a specialized microenvironment which facilitates the capture and
killing of bacteria.
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THE NET COMPONENT PROTEINS
Using a proteomic approach, Urban et al. identified 24 NET-
associated proteins (Urban et al., 2009). These proteins are;
nuclear components such as core histones; granular components
such as neutrophil elastase (ELANE), lactotransferrin (LTF),
cathepsin G (CTSG), myeloperoxidase (MPO), proteinase 3
(PRTN3), azurocidin 1 (AZU1), lysozyme C (LYZ), neutrophil
defensins, and cytoplasmic proteins. In other proteins, histone
H1, bactericidal permeability-increasing protein (BPI), pentraxin
3 (PTX3), and cathelicidin anti-microbial peptide (CAMP) are
also defined as NET component proteins (Brinkmann, 2004;
Jaillon et al., 2007; Lauth et al., 2009). Essentially all of these
proteins possess anti-microbial activity.
PTX3
GENOME
Breviario et al. identified PTX3 as one of the IL-1β -induced genes
in human umbilical vein endothelial cells (HUVECs) (Breviario
et al., 1992). The human PTX3 gene is located on chromosome
3q band 25, consists of 1861 base pairs, and is translated into 381
amino acids (Breviario et al., 1992). PTX3 belongs to the pen-
traxin family, which included the acute phase proteins C-reactive
protein (CRP) and serum amyloid P-component (SAP). As PTX3
has a longer N-terminal domain, it is classified as a member of the
long-pentraxin subfamily. Unlike the more common short pen-
traxins CRP and SAP, the PTX3 gene is highly conserved across
species (Garlanda et al., 2005). The PTX3 gene consists of three
exons, among which the first and second exons encode the sig-
nal sequence peptide and the N-terminal domain, and the third
exon encodes the C-terminal domain. In the promoter region of
the PTX3 gene, a number of potential enhancer binding sequences
(Pu-1, AP1, NF-κB, SP1, andNF-IL6) are located (He et al., 2007).
STRUCTURE
After the processing of the signal sequence of the translated 1–17
amino acids, the mature PTX3 consists of two domains, i.e.,
the N-terminal domain (18–178 a.a.) and C-terminal domain
(179–381 a.a.). The PTX3 C-terminal domain is a pentraxin-
like domain, which is conserved among the pentraxin family
with pentraxin signature (His-x-Cys-x-Ser/Thr-Trp-x-Ser). An
N-linked glycosylation site (Asn220) is located in the C-terminal
domain. In contrast to the C-terminal domain, the PTX3 N-
terminal domain is a unique sequence unrelated to other proteins.
The PTX3 protein forms an octamer via the inter-molecule disul-
fide bonds (Inforzato et al., 2008, 2010). Briefly, the N-terminal
domain participates in the organization of a tetramer, and the C-
terminal domain participates in the dimerization of the tetramer.
Interestingly, the N-terminal tetramer formation has two states;
a tetramer via the inter-disulfide bonds or non-covalent dimer-
ization of the inter-disulfide-bonded dimer. This results in the
asymmetric form of the full-length PTX3 (Inforzato et al., 2010).
EXPRESSION PATTERN
PTX3 mRNA expression is induced by primary inflamma-
tory signals in certain cells, such as myeloid dendritic cells
(Doni et al., 2003), peripheral blood leukocytes (Alles et al.,
1994), mononuclear macrophages/phagocytes (Alles et al., 1994;
Goodman et al., 2000), vascular endothelial cells (Breviario et al.,
1992; Lee et al., 1993), smooth muscle cells (Klouche et al., 2004),
fibroblasts (Lee et al., 1993; Goodman et al., 2000), adipocytes
(Abderrahim-Ferkoune et al., 2003), glial cells (Polentarutti et al.,
2000), cumulus oophorus cells (Salustri et al., 2004), mesan-
gial cells (Nauta et al., 2005), and synovial cells (Luchetti et al.,
2000). Transcriptional activation of PTX3 in response to the pro-
inflammatory cytokines TNFα and IL-1β is regulated by NF-κB
binding site in the PTX3 promoter (Altmeyer et al., 1995; Basile
et al., 1997). Other pathways also regulate PTX3 expression in a
cell- and signal-dependent manner. In detail, please refer to the
excellent reviews cited (He et al., 2007; Ortega-Hernandez et al.,
2009; Deban et al., 2011; Inforzato et al., 2011).
The characteristic PTX3 expression pattern is observed in
neutrophils. In mature neutrophils, the PTX3 protein is abun-
dantly present in granules, but PTX3 mRNA expression is
not detected. In contrast, PTX3 mRNA expression is observed
in progenitor neutrophils, such as promyelocytes and myelo-
cytes/metamyelocytes (Jaillon et al., 2007). As PTX3 protein
expression is observed in both neutrophil precursors and mature
neutrophils, it is considered that the PTX3 protein is produced
during the course of neutrophil maturation and mature neu-
trophils store it for use-on-demand. Immunostaining revealed
that PTX3 is present in neutrophil granules and that it colocalizes
with lactoferrin (Jaillon et al., 2007; Savchenko et al., 2011), sug-
gesting that PTX3 localizes to specific granules. The stored PTX3
in neutrophils is released upon E. coli, S. aureus or zymosan stim-
ulation, as well as PMA, ionomycin or TNFα treatment (Jaillon
et al., 2007; Savchenko et al., 2011; Daigo et al., 2012). PTX3
release is not induced by IL-1β or latex bead stimulation (Jaillon
et al., 2007). The released PTX3 localizes to NETs and plays a non-
redundant role in pathogen resistance. Thus, PTX3 in neutrophils
plays a distinctive role in the innate immune response due to its
rapid secretion, as well as by its unique pattern of ready-to-use
expression and storage.
CIRCULATING LEVELS
As the pentraxins CRP and SAP are well-known acute phase
proteins, PTX3 may also be an acute phase biomarker. Under
physiological conditions, the circulating PTX3 level is as low as
approximately 2 ng/mL (Yamasaki et al., 2009). Recently, many
studies on the circulating PTX3 level in clinical trials have been
reported. These reports indicate that the PTX3 levels are signifi-
cantly increased in certain infectious, cardiovascular, kidney, and
female reproductive system diseases as well as other disorders
(summarized in Table 1). In most cases, the PTX3 level correlates
with both the severity and survivability of the disorder. In these
diseases, the increases can reach up to 10∼100 times the control
level in severe inflammatory and infectious diseases such as sep-
sis. In the case of sepsis, the plasma PTX3 dramatically increases
to a level of up to 100 ng/mL (Muller et al., 2001) and the increase
correlates with mortality (Mauri et al., 2010).
Although not included in Table 1, there are other infec-
tious diseases, such as severe dengue virus infection (Mairuhu
et al., 2005) and meningococcal disease (Sprong et al., 2009),
in which the PTX3 levels are also increased. The PTX3 plasma
concentration is increased in patients with acute myocardial
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Table 1 | Circulating PTX3 levels measurements in clinical trials.
Disease category Diseases PTX3 concentration and significance References
Physiological level 2.00 (1.95, 2.04)a Yamasaki et al., 2009
Infectious diseases Systemic inflammatory response
syndrome (SIRS)
SIRS: 28.0 ± 5.6
Control: 1.04 ± 0.09b p < 0.005
Muller et al., 2001
Pulmonary tuberculosis (TB) TB: 3.21
Control: 0.98c p < 0.0001
Azzurri et al., 2005
Sepsis Sepsis: 26 (1, 202)
Control: 6 (1, 12)d p < 0.001
Hill et al., 2009
Febrile in the intensive/medium care
unit (ICU/MC) or ward
In ICU/MC: 44.4 (13.6, 105.9)
In ward: 14.2 (7.01, 25.1)
Control: 2.30 (1.66, 3.67)d p = 0.01
De Kruif et al., 2010
Bacteremia Non-survivor: 44.8 (10.7, 69.4)
Survivor: 6.4 (3.4, 13.5)d p < 0.001
Huttunen et al., 2011
Cardiovascular diseases Unstable angina pectoris (UAP) UAP: 6.09 (4.34–7.85)
Control: 2.30 (2.03–2.55)e p = 0.00003
Inoue et al., 2007
Chronic heart failure (CHF) CHF: 3.06 (2.38, 4.23)
Control: 1.91 (1.35, 2.60)d p = 0.001
Kotooka et al., 2008
Cardiac event: 6.0 (4.3, 9.3)
Event-free: 3.2 (2.0, 5.5)d p < 0.001
Ishino et al., 2008
Heart failure (HF) Cardiac event: 6.22 (5.59)
Event-free: 2.99 (2.95)d p < 0.001
Suzuki et al., 2008
HF: 3.28 (1.51, 2.90)
Non-HF: 2. 18 (1.51, 2.90)d p < 0.001
Matsubara et al., 2011
Coronary artery disease (CAD) CAD with inflammatory rheumatic disease (IRD):
1.96 ± 0.98
Control: 1.21 ± 0.59b p < 0.001
Hollan et al., 2010
Aortic valve stenosis (AS) AS: 3.5 ± 1.9
Control: 2.1 ± 0.8b p < 0.05
Naito et al., 2010
Acute coronary syndrome (ACS) ACS: 1.73 ± 0.82
Control: 0.50 ± 0.39b p < 0.001
Ustundag et al., 2011
ACS: 0.36 (0.225, 1.39)
Control: 0.015 (0, 0.06)f p < 0.0001
Kume et al., 2011
Hypertension Anti-hypertensive mediation
Pre-treatment: 35.25 ± 5.45
Post-treatment: 0.14 ± 0.19b p < 0.0001
Parlak et al., 2012
Acute ischemic strokes Non-survivor: 18.0 (8.2, 26.1)
Survivor: 6.4 (3.4, 11.8)d p < 0.001
Ryu et al., 2012
Giant cell arteritis (GCA) GCA: 23.31 ± 4.06
Control: 3.97 ± 0.28g p < 0.003
Baldini et al., 2012
Kidney diseases Hemodialysis (HD) HD: 3.03 ± 1.81
Uremic patients: 2.34 ± 1.19
Control 1.03 ±0.4b p < 0.001
Malaponte et al., 2007
HD: 1.87 (1.34, 2.50)
Control: 1.11 (0.86, 1.51)d p < 0.001
Xu et al., 2011
Renal transplant patients: 5.78 (1.09–20.36)
HD group: 1.65 (0.24–7.89)h p = 0.0001
Argani et al., 2012
(Continued)
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Table 1 | Continued
Disease category Diseases PTX3 concentration and significance References
Chronic kidney disease (CKD) Stage 5 CKD: 5.7 (0.9, 64.3)
Stage 3 to 4 CKD: 2.2 (0.4, 16.0)
Control: 1.8 (0.1, 9.1)d p < 0.001
Tong et al., 2007
Stage 5 CKD: 5.3 (1.0, 58.0)
Control: 1.8 (0.1, 9.2)d p < 0.001
Suliman et al., 2008
CKD: 7.7 (1.8, 32.9)
Control: 1.3 (0.1, 2.7)f p < 0.001
Yilmaz et al., 2010
CKD: 3.80 ± 2.35
Control: 2.15 ± 0.93b p < 0.0001
Nishi et al., 2011
CKD with periodontitis:
6.3380 ± 2.74875
CKD: 5.4100 ± 2.65296
Healthy: 1.8350 ± 0.75977b
p = 0.000
Pradeep et al., 2012
Female reproductive
system diseases
Preeclampsia (PE) PE: 13.8 (3.9, 32.3)
Control: 2.2 (1.2, 3.8)d p < 0.001
Cetin et al., 2006
PE: 22.64 (18.56, 26.34)
Control: 13.17 (8.55, 16.54)d
p < 0.001
Hamad et al., 2012
Pelvic inflammatory disease (PID) PID: 9.3 ± 1.01
Control: 2.27 ± 0.12b p < 0.001
Chang et al., 2011
Polycystic ovary syndrome (PCOS) PCOS: 1.0 ± 3.6
Control: 0.8 ± 0.8b p = 0.021
Aydogdu et al., 2012
Others Severe Psoriasis (sP) sP: 2.84 ± 0.94
Control: 1.22 ± 0.47b p < 0.0001
Bevelacqua et al., 2006
Ulcerative colitis (UC) and crohn’s disease (CD) Active UC: 8.22 ± 5.48
Active CD: 5.80 ± 3.59
Control: 1.76 ± 1.02b p < 0.05
Kato et al., 2008
Obesity Obesity: 0.99 ± 0.09
Control: 0.63 ± 0.05g p < 0.01
Miyaki et al., 2010
Central obesity in abdominal obesity patients Central obesity: 3.00 ± 2.61
Control: 1.33 ± 0.81b p < 0.01
Shim et al., 2010
Severe traumatic brain injury (TBI) non-survivors 9.95 (6.42)
Survivors 5.46 (4.87)b μg/mL
p < 0.001
Gullo Jda et al., 2011
Obstructive sleep apnea (OSA) Moderate-to severe OSA: 2.36
(1.79, 2.98)
Control: 1.53 (1.14, 2.04)f p < 0.01
Kasai et al., 2011
Schizophrenia (SZ) SZ with the metabolic syndrome:
388.2 (504.1)
SZ: 430.4 (523.0)
Control: 213.6 (524.0)d pg/mL
p < 0.001
Beumer et al., 2012
PTX3 concentrations are shown in ng/mL, unless indicated.
aGeometrical mean (confidence interval).
bMean ± SD.
cGeometrical mean.
d Median (interquartile range).
eMean (95% confidence interval).
f Median (25th percentile, 75th percentile).
gMean ± SEM.
hMedian (Minimum-Maximum).
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Table 2 | Responses to certain disorders in PTX3-knockout and PTX3-transgenic mice.
Category Experiment summary Result summary References
Lung injury Murine hepatitis virus strain 1 (MHV-1)
infection
Causing greater severity of acute lung injury (ALI)a Han et al., 2012
Ventilator-induced lung injury (VILI) Faster development of VILIb Real et al., 2012
LPS instillation Causing greater severity of ALIa Han et al., 2011
Vascular damage Coronary artery ligation and reperfusion Worsen heart damagea Salio et al., 2008
Atherogenic diet feed Increased atherosclerotic lesion area in PTX3 and
ApoE-double KO mice
Norata et al., 2009
Ischemia and reperfusion of the superior
mesenteric artery
Prevent tissue injury and mortalitya Souza et al., 2009
Increased tissue injury and mortalityb Souza et al., 2002
Infection LPS-induced endotoxemia Increased survival ratiob Dias et al., 2001
CLP-induced sepsis Increased survival ratiob Dias et al., 2001
Pulmonary infection by Aspergillus
fumigatus
Decreased survival ratioa Garlanda et al., 2002
Pulmonary infection by Klebsiella
pneumoniae
Faster lethality by a high inoculum administrationb Soares et al., 2006
Delayed lethality by a mid-to-low inoculum
administrationb
Soares et al., 2006
Murine cytomegalovirus (MCMV) infection More susceptible to MCMV infectiona Bozza et al., 2006
Influenza virus infection More susceptible to influenza virus infectiona Reading et al., 2008
Others Fas-deficient (lpr) C57BL/6 (B6) mice with
mild lupus-like autoimmunity
Aggravate autoimmune lung disease in PTX3-KO B6Lpr
mice
Lech et al., 2011
Kidney ischemia reperfusion injury Less kidney injury and inflammationa Chen et al., 2012
Subcutaneous injection of Matrigel
containing FGF2 and/or TSG-6
Abolishing of vascularization inhibition in PTX-KO mice Leali et al., 2012
Rolling interaction of PMNs in the
mesenteric venules
Increased rolling interaction frequencya Deban et al., 2010
Sexual system Subfertilea Varani et al., 2002
Kainate-induced seizures More widespread seizure-related neuronal damage in the
forebrain of PTX3-KO mice
Ravizza et al., 2001
aPTX3-knockout mouse study.
bPTX3-transgenic mouse study.
infarction (Peri et al., 2000). During pregnancy, the serum PTX3
level slightly increases as the pregnancy progresses (Larsson et al.,
2011). A higher PTX3 level is observed in preeclampsia (Cetin
et al., 2006; Rovere-Querini et al., 2006). Finally, the serum PTX3
level is reported to be a biomarker for lung carcinoma (Diamandis
et al., 2011). Thus, the circulating PTX3 level increases non-
specifically in various infections and inflammatory disorders. For
the purpose of diagnostic measurement, the dynamics of the
PTX3 complex, such as the NET component proteins should be
monitored (more details are discussed below).
FUNCTION
PTX3 has been postulated to play a variety of roles in innate
immunity, inflammatory regulation, and female fertility (Bottazzi
et al., 2006; Garlanda et al., 2009; Inforzato et al., 2011; Cieslik
and Hrycek, 2012). PTX3-knockout and transgenic mice stud-
ies have indicated that the predominant role of PTX3 occurs in
host protection in the case of lung injury, infection, vascular dam-
age, as well as certain other disorders (summarized in Table 2).
Briefly, the resistance against pathogens such as Aspergillus fumi-
gatus, Paracoccidioides brasiliensis, and Klebsiella pneumoniae has
been reported (Garlanda et al., 2002; Diniz et al., 2004; Soares
et al., 2006). In addition to its anti-pathogenic activity, PTX3 also
has been shown to play a role in protecting against severe inflam-
matory reactions in animal models of sepsis (Dias et al., 2001),
seizure-induced neurodegeneration (Ravizza et al., 2001) and
acute myocardial infarction (Salio et al., 2008). In addition, PTX3
participates in extracellular matrix deposition. PTX3 is involved
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in the organization of hyaluronan in the viscoelastic matrix of
cumulus oophorus (Scarchilli et al., 2007). It is considered that
these functions of PTX3 are exhibited synergistically along with
the binding of specific ligands (the details are provided in section
“Ligands”).
Of note, among the studies in PTX3-knockout and transgenic
mice, there are some reports of an opposite effect of PTX3 on
host-protection. In an intestinal ischemia and reperfusion model,
Souza et al. reported an increased injury and lethality in the
PTX3-transgenic mice that seemed to be associated with eleva-
tion of the TNFα concentration and aggravation of the inflam-
matory response (Souza et al., 2002). They also reported the
suppression of tissue injury and lethality after ischemic and reper-
fusion in PTX3-knockout mice. PTX3 administration to these
PTX3-knockout mice reversed this suppression (Souza et al.,
2009). Other groups have also reported an adverse effect of PTX3
in acute ischemic lung injury (Chen et al., 2012) and ventilator-
induced lung injury (Real et al., 2012). In the case of Klebsiella
pneumoniae infection, faster lethality was observed when a higher
inoculum was administered to PTX3-transgenic mice, but the
lethality was conversely delayed when a middle or low inoculum
was administered (Soares et al., 2006). Taking these bi-phasic
functions of PTX3 in host-defense into account, more detailed
accounts of the disease-specific mechanisms of PTX3 need to be
elucidated to achieve useful clinical applications.
LIGANDS
The multiple host-protective functions of PTX3 arise from the
capacity for the recognition and binding to ligands. The reported
PTX3 ligands are classified as follows: (1) complement compo-
nents; (2) Fungi, bacteria, microbial components, and viruses;
(3) selectin P; (4) extracellular matrix proteins and (5) growth
factors (Presta et al., 2007; Mantovani et al., 2008; Deban et al.,
2009; Moalli et al., 2011). Some of these ligands bind to PTX3 in
a PTX3-domain specific manner, while others require full-length
PTX3 for binding (Deban et al., 2009; Bottazzi et al., 2010).
Table 3 | List of the NET component proteins and proteins belonging to the PTX3 complex.
NET component proteins Proteomic identification of
PTX3 complex in sepsis
Cellular localization Protein name Gene name
Granules Neutrophil elastase ELANE
Lactotransferrin LTF
Azurocidin AZU1 Yes
Cathepsin G CTSG
Myeloperoxidase MPO Yes
Proteinase 3 PRTN3
Lysozyme C LYZ
Neutrophil defensin 1 and 3 DEFA1 and 3 Yes (DEFA1)
Pentraxin 3 PTX3 Target protein
Bactericidal permeability-increasing protein BPI
Cathelicidin anti-microbial peptide CAMP
Nucleus Histone H1 H1F0
Histone H2A H2A Yes
Histone H2B H2B
Histone H2B-like H2B
Histone H3 H3 Yes
Histone H4 H4 Yes
Myeloid cell nuclear differentiation antigen MNDA
Cytoplasm S100 calcium-binding protein A8 S100A8
S100 calcium binding protein A9 S100A9
S100 calcium-binding protein A12 S100A12
Cytoskeleton Actin (beta and/or gamma 1) ACTB, ACTG1 Yes
Myosin-9 MYH9 Yes
Alpha-actinin (1 and/or -4) ACTN1, ACTN4
Plastin-2 LCP1
Cytokeratin-10 KRT10 Yes
Peroxisomal Catalase CAT
Glycolytic enzymes Alpha-enolase ENO1 Yes
Transketolase TKT Yes
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1. PTX3 binds to certain select complement components,
such as C1q (Inforzato et al., 2006), C4b-binding proteins
(Braunschweig and Józsi, 2011), ficolins (Ma et al., 2009;
Gout et al., 2011), mannose-binding lectin 2 (MBL) (Ma
et al., 2011), factor H (Deban et al., 2008; Kopp et al.,
2012), factor H-like protein 1 (Kopp et al., 2012) and factor
H-related protein 1 (Kopp et al., 2012) for the regulation of
the complement pathways in the innate immune response. The
interaction of PTX3 and C1q elicits a dual consequence in
the classical complement pathway. When C1q binds to immo-
bilized PTX3, the classical complement pathway is activated;
however, the binding of C1q to PTX3 in the fluid phase inhibits
complement activation (Nauta et al., 2003). PTX3 can also
activate the lectin pathway by binding to the ficolins andMBL.
PTX3 enhances complement deposition by ficolin-2 on the
Aspergillus fumigatus surface (Ma et al., 2009), and PTX3-MBL
binding enhanced C4 and C3 deposition as well as the phago-
cytosis of Candida albicans (Ma et al., 2011). PTX3 is not only
involved in complement activation, but also acts as a comple-
ment inhibitor to regulate excessive complement activation by
binding to C4b-binding proteins and factor H. Please refer to
the review by Doni et al. for more detail (Doni et al., 2012).
2. In the protection afforded against infection, PTX3 recog-
nizes certain fungi, bacteria, microbial moieties, and viruses.
PTX3 binds to microbial pathogens such as Pseudomonas
aeruginosa (Garlanda et al., 2002), Salmonella typhimurium
(Garlanda et al., 2002), Aspergillus fumigatus (Garlanda et al.,
2002), and Paracoccidioides brasiliensis (Diniz et al., 2004).
PTX3-knockout mice are susceptible to invasive pulmonary
aspergillosis due to inappropriate Th1 and Th2-helper-cell-
mediated resistance (Garlanda et al., 2002). Macrophages
from PTX3-transgenic mice exhibit improved phagocytosis of
Paracoccidioides brasiliensis as well as an enhancement of the
production of nitric oxide (NO) (Diniz et al., 2004). PTX3
also binds to outer membrane protein A from Klebsiella pneu-
moniae (KpOmpA) in order to modulate the inflammatory
response triggered by KpOmpA (Jeannin et al., 2005). PTX3
binds to cytomegalovirus and influenza virus type A for the
inhibition of infection (Bozza et al., 2006; Reading et al., 2008).
Upon binding to influenza virus, PTX3 exerts anti-viral activ-
ity by the inhibition of hemagglutination, the neutralization
of virus infectivity and the inhibition of viral neuraminidase
(Reading et al., 2008).
3. As an inflammatory modulator, PTX3 binds to selectin P. The
N-linked glycosidic moiety of PTX3 contributes to the binding
of selectin P, and this binding dampens neutrophil recruitment
at the sites of inflammation (Deban et al., 2010). Importantly,
in a model of acid-induced acute lung injury, both exoge-
nous PTX3 and endogenously released PTX3 administration
suppress neutrophil recruitment (Deban et al., 2010). This
suggests a negative feedback role of PTX3 that dampens the
excessive neutrophil recruitment via selectin P.
4. PTX3 takes part in extracellular matrix formation by binding
to TNFα-induced protein 6 (TNFAIP6 or TSG-6) and inter-
α-trypsin inhibitor (IαI) (Salustri et al., 2004; Scarchilli et al.,
2007; Ievoli et al., 2011). PTX3-knockout mice exhibit a defect
in female fertility because of the defects in ovulation (Varani
et al., 2002) and the organization of the cumulus oophorus
extracellular matrix (Salustri et al., 2004). The PTX3-TSG-6
and PTX3-IαI binding events are considered to be essential
for the organization of hyaluronan in the viscoelastic matrix of
cumulus oophorus (Inforzato et al., 2011; Moalli et al., 2011).
5. PTX3 binding to fibroblast growth factor 2 (FGF-2) regulates
endothelial cell proliferation and angiogenesis, smooth mus-
cle cell (SMC) activation, and intima thickening after arterial
injury (Rusnati et al., 2004; Camozzi et al., 2005). PTX3-FGF2
binding can inhibit the proliferation and chemotactic activ-
ity of FGF2 in SMCs by interfering with the interaction of the
FGF2 and FGF receptors (Camozzi et al., 2005).
Taking these results, it is clear that the protective effects of
PTX3 are realized in coordination with specific PTX3 ligands.
Therefore, we carried out a proteome-wide identification of
PTX3 ligands and complexes in septic patient serum and plasma.
FIGURE 1 | Schematic relationship and role of PTX3 and NET
component proteins in pathogen recognition and clearance. NET
component proteins which were identified as PTX3 complex (Daigo et al.,
2012) are associated PTX3 in NETs. Among these, the confirmed direct
interaction of AZU1 and MPO to PTX3, and formerly reported histone-PTX3
interaction (Garlanda et al., 2005) are designated by two-way arrows. These
bindings facilitate pathogen clearance efficiency of AZU1 and MPO. The
pathogen recognition and anti-pathogenic action are designated by open
arrow and closed arrow in box, respectively. Two-way arrows with dashed
lines designate other potential interactions to PTX3. The indirect
association to DNA via histone or basic proteins such as DEFA1, AZU1, and
MPO, which DNA associations are designated by dashed lines, maintains
PTX3 localization in NETs. PTX3, pentraxin 3; DEFA1, neutrophil defensin 1;
MYH9, Myosn-9; KRT10, Cytokeratin-10; AZU1, azurocidin 1; MPO:
myeloperoxidase.
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PTX3 and its complex component proteins were immunoprecipi-
tated by anti-PTX3 antibody-crosslinked magnetic beads, and the
isolated fractions were subjected to shotgun proteomics analysis
for label-free relative quantitation via spectral counting (Daigo
et al., 2012). The identified proteins included the known PTX3
ligands such as C1q, ficolins, TSG-6, and IαI, as mentioned above.
Additionally, the ficolin-binding proteins of mannan-binding
lectin serine protease 1 and 2 (MASP1 and MASP2) (Ma et al.,
2009), and the TSG-6 binding proteins of the versican core pro-
tein (VCAN) and thrombospondin-1 (THBS1) (Salustri et al.,
2004) were included in the proteins that were identified. As these
proteins were identified in pooled normal human plasma with
artificially spiked recombinant PTX3, these appear to be sta-
ble circulating PTX3 complexes. Nevertheless, the disease-specific
dynamics of these binding levels need to be investigated further,
as do the specific functions of these PTX3 complexes in sepsis.
NET COMPONENT PROTEINS AS PTX3 LIGANDS: A NEWLY
RECOGNIZED PROTECTIVE ROLE
In the effort to identify the PTX3 ligand in septic patient flu-
ids, a novel finding is that the NET component proteins were
included (Daigo et al., 2012) (Table 3). A detailed investigation
revealed that azurocidin 1 (AZU1) and myeloperoxidase (MPO)
directly bind to PTX3. AZU1 and MPO belong to the NET
component proteins (Urban et al., 2009) and exert bacterici-
dal activity (Watorek, 2003; Klebanoff, 2005). AZU1 preferably
binds to the PTX3 N-terminal domain, with a pattern of calcium
ion dependency. In contrast to AZU1, MPO binds to both the
PTX3 N-terminal and C-terminal domains, and does not require
calcium ions. Further investigation of the PTX3-AZU1 interac-
tion revealed that the AZU1 binding affinity to PTX3 was 22 ±
7.6 nM, and that AZU1 and PTX3 are partially co-localized in
NETs (Daigo et al., 2012).
From these results, it is suggested that PTX3 may enhance
the bactericidal efficiency of AZU1 and MPO in terms of both
pathogen recognition and AZU1 and MPO binding (Figure 1).
The mechanism by which PTX3 localizes in NETs has not yet been
determined, but it is possible that PTX3 localization arises from
an interaction with histones or the basic proteins AZU1, MPO,
and defensin, along with a simultaneous association between
these basic proteins and DNA (Figure 1). It is not clear at present
whether the PTX3-AZU1 and PTX3-MPO binding events in the
bloodstream take place within or outside of NETs. Either or even
both of these are possible, and these complexes may be active in
pathogen recognition and also involved in clearance. In septic
patients, the plasma levels of AZU1 are increased, but do not
significantly correlate with mortality (Berkestedt et al., 2010).
As useful biomarkers of sepsis not yet available (Pierrakos and
Vincent, 2010), the binding levels of PTX3-AZU1 and PTX3-
MPO in septic plasma have the important potential to fulfill this
purpose.
CONCLUSION
Recent proteomic investigation of the circulating PTX3 complex
components has revealed new and pivotal roles of PTX3 in the
innate immune response, along with a pattern of binding to the
NET component proteins. In NETs, PTX3 brings the NET com-
ponent proteins into close proximity with the pathogens that
PTX3 capture in order to enhance pathogen clearance. Also, in the
bloodstream, PTX3 forms a complex with bactericidal proteins
for the recognition and clearance of pathogens. These activities of
PTX3 in concert contribute to the host-protective effect. In addi-
tion, the dynamic changes that occur in PTX3 and its complex
proteins may become specific biomarker for severe inflammatory
diseases.
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